Quantcast

Latest Natalizumab Stories

2006-03-08 15:07:29

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec's multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect. If the Food and Drug Administration followed the recommendation, it would signal a reversal of fortune for Biogen and partner Elan Corp. of Ireland, and a victory for MS patients who have pleaded for...

2006-03-08 13:36:22

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri can return to the market as long as there are safeguards to closely monitor patients for a life-threatening side effect, a U.S. advisory panel unanimously said on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended Tysabri sales in February 2005 after three patients developed a rare brain and spinal cord infection and two of them died. Members of the U.S. Food and...

2006-03-08 11:45:00

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan Corp.'s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday. Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection. Two of them died.

2006-03-08 12:35:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended sales in February 2005 after three patients developed a brain and spinal cord infection known as progressive multifocal leukoencephalopathy, or PML. Two of the patients...

2006-03-08 11:55:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended sales in February 2005 after three patients developed a brain and spinal cord infection known as progressive multifocal leukoencephalopathy, or PML. Two of the patients...

2006-03-08 10:59:41

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 10:50:18

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 10:49:50

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 01:23:31

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A U.S. advisory panel is set to decide on Wednesday whether to urge the return of a Biogen Idec multiple sclerosis drug that was pulled from the market last year when it was linked to a rare, life-threatening infection. The drug, Tysabri, is key for Biogen and marketing partner Elan Corp. It had been dubbed a billion-dollar-a-year seller before the safety concern arose. The companies voluntarily suspended sales in February 2005...

2006-03-07 18:30:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Multiple sclerosis patients appealed for the return of a Biogen Idec drug on Tuesday, telling U.S. advisers they would risk a life-threatening side effect for the chance at relief from disabling symptoms. Biogen and marketing partner Elan Corp voluntarily suspended sales of the drug, Tysabri, in February 2005 after three patients developed a rare brain and spinal cord infection. Two of the cases were fatal. In sometimes tearful testimony...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related